MovDisordV3, PascalFrancis, Corpus, bibRecord, 002567

Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study

Identifieur interne : 002567 ( PascalFrancis/Corpus ); précédent : 002566; suivant : 002568

Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study

Auteurs : H. Christopher Hyson ; Andrew M. Johnson ; Mandar S. Jog

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:03-0040823

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Sialorrhée, Atropine, Parasympatholytique, Voie sublinguale, Chimiothérapie, Traitement, Homme, Etude préalable.

English descriptors

KwdEn :
- Atropine, Chemotherapy, Human, Parasympatholytic, Parkinson disease, Previous study, Sialorrhea, Sublingual administration, Treatment.

Abstract

Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, I with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η² = 0.636), and between baseline and I week, t(6) = 4.583 P < 0.005 (η² = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (η² = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study`
A11	`01`	`1`		`@1 HYSON (H. Christopher)`
A11	`02`	`1`		`@1 JOHNSON (Andrew M.)`
A11	`03`	`1`		`@1 JOG (Mandar S.)`
A14	`01`			`@1 Movement Disorders Program, London Health Sciences Centre @2 London, Ontario @3 CAN @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 University of Western Ontario @2 London, Ontario @3 CAN @Z 2 aut.`
A20				`@1 1318-1320`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000105559450260`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 12 ref.`
A47	`01`	`1`		`@0 03-0040823`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, I with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η² = 0.636), and between baseline and I week, t(6) = 4.583 P < 0.005 (η² = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (η² = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Sialorrhée @5 04`
C03	`02`	`X`	`ENG`	`@0 Sialorrhea @5 04`
C03	`02`	`X`	`SPA`	`@0 Sialorrea @5 04`
C03	`03`	`X`	`FRE`	`@0 Atropine @2 NK @2 FR @5 07`
C03	`03`	`X`	`ENG`	`@0 Atropine @2 NK @2 FR @5 07`
C03	`03`	`X`	`SPA`	`@0 Atropina @2 NK @2 FR @5 07`
C03	`04`	`X`	`FRE`	`@0 Parasympatholytique @5 08`
C03	`04`	`X`	`ENG`	`@0 Parasympatholytic @5 08`
C03	`04`	`X`	`SPA`	`@0 Parasimpatolítico @5 08`
C03	`05`	`X`	`FRE`	`@0 Voie sublinguale @5 10`
C03	`05`	`X`	`ENG`	`@0 Sublingual administration @5 10`
C03	`05`	`X`	`SPA`	`@0 Vía sublingual @5 10`
C03	`06`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`06`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`06`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`09`	`X`	`FRE`	`@0 Etude préalable @5 23`
C03	`09`	`X`	`ENG`	`@0 Previous study @5 23`
C03	`09`	`X`	`SPA`	`@0 Estudio previo @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Voie administration @5 61`
C07	`06`	`X`	`ENG`	`@0 Route of administration @5 61`
C07	`06`	`X`	`SPA`	`@0 Vía administración @5 61`
N21				`@1 020`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0040823 INIST
ET :	Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study
AU :	HYSON (H. Christopher); JOHNSON (Andrew M.); JOG (Mandar S.)
AF :	Movement Disorders Program, London Health Sciences Centre/London, Ontario/Canada (1 aut., 3 aut.); University of Western Ontario/London, Ontario/Canada (2 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 6; Pp. 1318-1320; Bibl. 12 ref.
LA :	Anglais
EA :	Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, I with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η² = 0.636), and between baseline and I week, t(6) = 4.583 P < 0.005 (η² = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (η² = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.
CC :	002B17G
FD :	Parkinson maladie; Sialorrhée; Atropine; Parasympatholytique; Voie sublinguale; Chimiothérapie; Traitement; Homme; Etude préalable
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Voie administration
ED :	Parkinson disease; Sialorrhea; Atropine; Parasympatholytic; Sublingual administration; Chemotherapy; Treatment; Human; Previous study
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Route of administration
SD :	Parkinson enfermedad; Sialorrea; Atropina; Parasimpatolítico; Vía sublingual; Quimioterapia; Tratamiento; Hombre; Estudio previo
LO :	INIST-20953.354000105559450260
ID :	03-0040823

Links to Exploration step

Pascal:03-0040823

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation><inist:fA14 i1="02"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0040823</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 03-0040823 INIST</idno>
<idno type="RBID">Pascal:03-0040823</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002567</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation><inist:fA14 i1="02"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atropine</term>
<term>Chemotherapy</term>
<term>Human</term>
<term>Parasympatholytic</term>
<term>Parkinson disease</term>
<term>Previous study</term>
<term>Sialorrhea</term>
<term>Sublingual administration</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Sialorrhée</term>
<term>Atropine</term>
<term>Parasympatholytique</term>
<term>Voie sublinguale</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude préalable</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, I with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η<sup>2</sup>
 = 0.636), and between baseline and I week, t(6) = 4.583 P < 0.005 (η<sup>2</sup>
 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (η<sup>2</sup>
 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HYSON (H. Christopher)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JOHNSON (Andrew M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JOG (Mandar S.)</s1>
</fA11>
<fA14 i1="01"><s1>Movement Disorders Program, London Health Sciences Centre</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>1318-1320</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000105559450260</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>12 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0040823</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, I with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η<sup>2</sup>
 = 0.636), and between baseline and I week, t(6) = 4.583 P < 0.005 (η<sup>2</sup>
 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (η<sup>2</sup>
 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Sialorrhée</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Sialorrhea</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sialorrea</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Atropine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Atropine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Atropina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parasympatholytique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parasympatholytic</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parasimpatolítico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Voie sublinguale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Sublingual administration</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vía sublingual</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude préalable</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Previous study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio previo</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Voie administration</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Route of administration</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Vía administración</s0>
<s5>61</s5>
</fC07>
<fN21><s1>020</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0040823 INIST</NO>
<ET>Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study</ET>
<AU>HYSON (H. Christopher); JOHNSON (Andrew M.); JOG (Mandar S.)</AU>
<AF>Movement Disorders Program, London Health Sciences Centre/London, Ontario/Canada (1 aut., 3 aut.); University of Western Ontario/London, Ontario/Canada (2 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 6; Pp. 1318-1320; Bibl. 12 ref.</SO>
<LA>Anglais</LA>
<EA>Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, I with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η<sup>2</sup>
 = 0.636), and between baseline and I week, t(6) = 4.583 P < 0.005 (η<sup>2</sup>
 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (η<sup>2</sup>
 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Sialorrhée; Atropine; Parasympatholytique; Voie sublinguale; Chimiothérapie; Traitement; Homme; Etude préalable</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Voie administration</FG>
<ED>Parkinson disease; Sialorrhea; Atropine; Parasympatholytic; Sublingual administration; Chemotherapy; Treatment; Human; Previous study</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Route of administration</EG>
<SD>Parkinson enfermedad; Sialorrea; Atropina; Parasimpatolítico; Vía sublingual; Quimioterapia; Tratamiento; Hombre; Estudio previo</SD>
<LO>INIST-20953.354000105559450260</LO>
<ID>03-0040823</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002567 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002567 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0040823
   |texte=   Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study

Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri